Alexion Pharmaceuticals, Inc has announced the submission of a biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of ALXN1210, the company’s investigational ...

“It can take months, and sometimes years, to receive a correct diagnosis for PNH — a chronic, progressive and potentially life-threatening rare disease – which can be an overwhelming experience for ...

For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Industry watchers never settled on what to make of Ultomiris’ opportunity in ALS because the drug entered phase 3 without proof-of-concept data. (AstraZeneca/Alexion) () Bad news has struck first for ...

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients. A biologic medicine, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Alexion Pharmaceuticals, Inc has announced that positive results from one of the two large phase 3 studies of ALXN1210, the company's investigational long-acting C5 complement inhibitor, in patients ...